Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis

Background: Natalizumab (NAT) is a high-efficacy treatment for relapsing remitting multiple sclerosis (RRMS). However, it is associated with an increased risk of progressive multifocal leukoencephalopathy that sometimes requires treatment cessation with a risk of returning disease activity. The aim...

Full description

Bibliographic Details
Main Authors: Undine Proschmann, Hernan Inojosa, Katja Akgün, Tjalf Ziemssen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
natalizumab (TYSABRI)
natalizumab concentration
neurofilament light (NFL) chain
recurrence of disease activity
cessation of natalizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2021.650530/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2021.650530/full

Similar Items